Fig. 1

Domatinostat can sensitize pancreatic cancer cells to chemotherapeutics treatment. CI (combination index) values (mean ± SD from at least three separate experiments performed in quadruplicates) computed at 50% of cell kill (CI₅₀) CalcuSyn software after 96 h. Two schedules of treatment were represented in PANC1, PANC28 and ASPC1 cell lines. Equitoxic doses of drugs with domatinostat administered at same time with chemotherapy (in figure domatinostat CON) and equitoxic doses of drugs with domatinostat administered 24 h before the same chemotherapy (in figure domatinostat SEQ). In A. 5’DFUR, SN-38 and oxaliplatin plus domatinostat combinations were reported, in B. gemcitabine and taxol plus domatinostat combinations were reported. The combinations were considered synergistic when CIs were below 0.9 and additive when CIs were below 1.1 C.-D. DRI (doses reduction index) values (mean ± SD from at least three separate experiments performed in quadruplicates) computed at 50% of cell kill (DRI₅₀) CalcuSyn software after 96 h in PANC1, PANC28 and ASPC1 cells. In C. DRI₅₀ for 5’DFUR, SN-38 and oxaliplatin plus domatinostat combinations. In D. DRI₅₀ for gemcitabine and taxol plus domatinostat combinations. E.-F. ASPC1, PANC1 and PANC28 cells were treated for 96 h with increasing concentration of domatinostat alone and in combination with increasing concentration of Gemcitabine/Taxol (GT) (doses are reported in figure). Cell growth expressed as percentage of control was assessed by sulforhodamine B colorimetric assay (see Materials and Methods)